Amid a growing number of me-too devices, one company that is differentiating itself in the market for stroke thrombectomy is Route 92 Medical (R92). Adam Hattan, R92’s vice president of marketing, discusses R92’s novel system for mechanical thrombectomy and competing in the market for stroke interventions in an interview with SmartTRAK at the Society of Neurointerventional Surgery (SNIS) 19th Annual Meeting held in Toronto, Canada July 25-29, 2022.
To find out more about R92, its Monopoint operating platform and the Company’s strategies for growth, click on the following video recorded live at SNIS 2022. (10:13 min). A link to download a transcript of the interview is also provided below.
SmartTRAK: Hi. This is Anne Staylor, executive editor for SmartTRAK. I'm here at the SNIS meeting in Toronto. Today, I'm talking with Adam Hattan, vice president of marketing for Route 92 Medical. Adam, thank you for talking with me.
Adam Hattan: Thank you for having me.
Well, it seems Route 92's been around a while, but the company has been in stealth mode until recently. Can you give me some background on the company and where you're at in terms of bringing your products to market?
AH: We've been in development phase for about five years. The company originated from ideas that were generated from Silk Road and Tony Chow, his days as a CEO of the company. It spun out of there. We've been working for the last five years on perfecting the catheters, making them perform, making the system perform, because we're really approaching the procedure of mechanical thrombectomy from a whole new angle, where we redesigned the procedure from top to bottom. So our devices include ...
To download the complete transcript of Route 92 Medical's Adam Hattan's interview "Reimagining the Road to Stroke Interventions" just click the button below.